Expert Consultations: Real-World Answers

Atypical Psychopharmacologic Strategies for Children and Adolescents – Interview

Published on July 1, 2023 Certification expiration date: July 1, 2026

Guest

Richard Seeber

To unlock this audio you need to become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Although atypical psychopharmacologic strategies may be useful in the treatment of various conditions among children and adolescents, it is always important to individualize treatment for patients.
Low-dose topiramate is generally better tolerated by children and adolescents compared with adults, but it is still important to watch out for side effects, such as cognitive impairment.
Use of antihistamines for the management of insomnia and sleep difficulties should be limited to the short term and always complemented with sleep hygiene techniques.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features David Rosenberg, M.D., professor and Chair of the Department of Psychiatry and Behavioral Neurosciences at Wayne State University School of Medicine, in Detroit, Michigan, where he also holds the Miriam L. Hamburger Endowed Chair of Child Psychiatry. He

Unlock this Expert Consultation and earn 0.75 CMEs
Become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

Recognize the importance of an individualized approach when it comes to initiating and dosing atypical psychopharmacologic agents for the pediatric population.
Discuss the relevant evidence base behind the use of specific agents for clinical concerns, such as obsessive-compulsive disorder, self-injurious and substance use behaviors, and insomnia.

Original Release Date: July 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: July 1, 2026

Expert: David Rosenberg, M.D.

Medical Editors: Richard Seeber, M.D., Melissa Mariano, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-prod.psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

David R. Rosenberg, M.D.